Department of Pharmacology, Faculty of Medicine, Minia University, El-Minia, Egypt.
Department of Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt.
Hum Exp Toxicol. 2020 Jul;39(7):906-919. doi: 10.1177/0960327120905957. Epub 2020 Feb 13.
Sepsis is one of the most common causes of death among hospitalized patients. Activity of xanthine oxidase (XO), a reactive oxygen species-producing enzyme, is known to be elevated in septic patients. Our aim was to investigate the possible protective role of XO inhibitor, febuxostat (FEB), in a rat model of sepsis-induced liver and kidney injures. Adult male albino rats were divided into four groups ( = 12 each): sham control, sham + FEB, cecal ligation and puncture (CLP), and CLP + FEB groups. FEB (10 mg/kg per os (p.o.)) was given once daily for 2 days and 30 min prior to laparotomy with CLP. CLP was associated with a high mortality rate accompanied by significant liver and kidney injuries indicated by elevated serum alanine aminotransferase, aspartate aminotransferase, urea, and creatinine levels and confirmed by histopathological tissue injury. Moreover, there was an increase in neutrophil gelatinase-associated lipocalin, uric acid, malondialdehyde, and nitric oxide levels and with decreased superoxide dismutase activity and total antioxidant capacity. In addition, CLP caused increased expression of the inflammatory markers tumor necrosis factor alpha, interleukin 1beta protein levels, and nuclear factor kappa B immunoexpression. Finally, CLP operated rats exhibited an upregulation in the apoptotic mediators, caspase 3, and P-C-Jun N-terminal kinases (JNK) proteins. FEB treatment of CLP rats caused a significant improvement and normalization in all measured parameters. Moreover, FEB amerliorates degenerative histopathological changes and improves the overall survival rate. In conclusion, FEB exhibited a protective effect in sepsis-induced liver and kidney injuries most probably through its anti-inflammatory, antioxidant, and antiapoptotic properties and attenuating JNK signaling pathway secondary to its XO enzyme inhibitory activity.
脓毒症是住院患者死亡的最常见原因之一。已知黄嘌呤氧化酶(XO),一种产生活性氧物质的酶,在脓毒症患者中活性升高。我们的目的是研究黄嘌呤氧化酶抑制剂非布司他(FEB)在脓毒症诱导的肝和肾损伤大鼠模型中的可能保护作用。成年雄性白化大鼠分为四组(每组 n = 12):假手术对照组、假手术+FEB 组、盲肠结扎穿孔(CLP)组和 CLP+FEB 组。FEB(10mg/kg 口服(p.o.))每天给药一次,共 2 天,并在 CLP 剖腹术前 30 分钟给药。CLP 与高死亡率相关,并伴有血清丙氨酸氨基转移酶、天冬氨酸氨基转移酶、尿素和肌酐水平升高以及组织损伤的组织病理学证实的显著肝和肾损伤。此外,中性粒细胞明胶酶相关脂质运载蛋白、尿酸、丙二醛和一氧化氮水平升高,超氧化物歧化酶活性和总抗氧化能力降低。此外,CLP 导致炎症标志物肿瘤坏死因子-α、白细胞介素 1β蛋白水平和核因子 kappa B 免疫表达增加。最后,CLP 操作大鼠表现出凋亡介质 caspase 3 和 P-C-Jun N-末端激酶(JNK)蛋白的上调。FEB 治疗 CLP 大鼠可显著改善和正常化所有测量参数。此外,FEB 改善了退行性组织病理学变化并提高了总体生存率。总之,FEB 通过其抗炎、抗氧化和抗凋亡特性以及减轻 JNK 信号通路(继发于其 XO 酶抑制活性),在脓毒症诱导的肝和肾损伤中表现出保护作用。